Faron, etusivu

releases and publications

Faron hits key milestone with BEXMAB Phase 2 completion, advances to registrational trial with FDA alignment

Faron Pharmaceuticals Ltd: Approval of Share Subscriptions Based on Special Rights in connection with Advanced Amortisation of the First Tranche Bonds

Regulatory

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

Shareholder announcement Regulatory

Updated BEXMAB Phase I/II Data presented at ESMO 2025 shows further improvement, strengthening the clinical profile of bexmarilimab in treatment-naïve HR-MDS patients

Regulatory

Faron Pharmaceuticals Ltd: Registration of New Shares

Regulatory

Faron Pharmaceuticals Ltd: Approval of Share Subscriptions Based on Special Rights in connection with Amortisation of the First Tranche Bonds

Regulatory

Faron Pharmaceuticals Ltd: Exercise of Options, Director Dealing and Issue of Equity

Insider Transaction Regulatory

Correction: FARON PHARMACEUTICALS LTD: HALF-YEAR FINANCIAL RESULTS 1 JANUARY – 30 JUNE 2025

Regulatory

FARON PHARMACEUTICALS LTD: HALF-YEAR FINANCIAL RESULTS 1 JANUARY – 30 JUNE 2025

Regulatory

Faron Pharmaceuticals Ltd: Notice of Half-Year Financial Results

Regulatory
PreviousNext
Back to top